Biogen Inc. (NASDAQ:BIIB) Overview: Key Developments and Financial Performance
Biogen(US:BIIB) Financial Modeling Prep·2026-01-07 07:08Biogen's collaboration with Eisai Co., Ltd. on Alzheimer's treatment "LEQEMBI" marks a significant stride in neurological disease management.The acceptance of the Biologics License Application for LEQEMBI in China could open new market opportunities for Biogen.Biogen's stock has seen a 15.1% increase in 2025, driven by successful product launches and a 29.9% increase in sales for Skyclarys.Biogen Inc. (NASDAQ:BIIB) is a leading biotechnology company with a focus on developing treatments for neurological dis ...